

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alcassedan, Virginia 22313-1450 www.emplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/630,223	07/30/2003	Francis Michon	13564-105038US1	8301
65989 7590 09/24/2009 KING & SPALDING		9	EXAMINER	
1185 AVENU	E OF THE AMERICAS		DEVI, SARVAMANGALA J N	
NEW YORK,	NY 10036-4003		ART UNIT	PAPER NUMBER
			1645	•
			NOTIFICATION DATE	DELIVERY MODE
			09/24/2009	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

usptomailnyc@kslaw.com

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/630,223	MICHON ET AL.		
Examiner	Art Unit		
S. Devi, Ph.D.	1645		

	S. Devi, Ph.D.	1645					
The MAILING DATE of this communication appe	ars on the cover sheet with the o	orrespondence add	ress				
THE REPLY FILED 09 September 2009 FAILS TO PLACE THIS	S APPLICATION IN CONDITION F	OR ALLOWANCE.					
<ol> <li>M The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following r application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:</li> </ol>	the same day as filing a Notice of a eplies: (1) an amendment, affidavi al (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request				
a) The period for reply expiresmonths from the mailing	date of the final rejection.						
The period for reply expires on: (1) the mailing date of this Ai no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (1).	iter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	date of the final rejection	n.				
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	).						
Extensions of time may be obtained under 37 CFR 1,136(a). The date have been filled is the date for purposes of determining the period often during 47 CFR 1,17(a) is calculated from: (1) the expiration date of the s set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1,704(b). NOTICE OF APPEAL.	ension and the corresponding amount of hortened statutory period for reply origi	of the fee. The appropria nally set in the final Offic	ite extension fee action; or (2) as				
2. The Notice of Appeal was filed on 09 September 2009. A							
the date of filing the Notice of Appeal (37 CFR 41.37(a)), o							
appeal. Since a Notice of Appeal has been filed, any reply AMENDMENTS	must be filed within the time period	set forth in 37 CFR 4	11.37(a).				
3. The proposed amendment(s) filed after a final rejection, b	out prior to the date of filing a brief.	will not be entered be	cause				
(a) They raise new issues that would require further con							
(b) ☐ They raise the issue of new matter (see NOTE below	v);						
(c) They are not deemed to place the application in bett	er form for appeal by materially red	lucing or simplifying th	e issues for				
appeal; and/or		and delice					
(d) They present additional claims without canceling a c	orresponding number of finally reje	ected claims.					
NOTE: (See 37 CFR 1.116 and 41.33(a)).							
<ol> <li>The amendments are not in compliance with 37 CFR 1.12</li> </ol>		mpliant Amendment (F	PTOL-324).				
<ol><li>Applicant's reply has overcome the following rejection(s):</li></ol>							
<ol> <li>Newly proposed or amended claim(s) would be all- non-allowable claim(s).</li> </ol>	owable if submitted in a separate, t	imely filed amendmer	t canceling the				
<ol> <li>For purposes of appeal, the proposed amendment(s): a) thou the new or amended claims would be rejected is proving.</li> </ol>		be entered and an ex	planation of				
The status of the claim(s) is (or will be) as follows: Claim(s) allowed: None.							
Claim(s) allowed. <u>None.</u> Claim(s) objected to:							
Claim(s) rejected: 1-8.10.11 and 42-46.							
Claim(s) withdrawn from consideration: 12-41,47-51 and 5	<u>3-55</u> .						
AFFIDAVIT OR OTHER EVIDENCE							
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>							
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary</li> </ol>	vercome <u>all</u> rejections under appea	l and/or appellant fails	to provide a				
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	of the status of the claims after er	ntry is below or attache	ed.				
The request for reconsideration has been considered but See Continuation Sheet.	does NOT place the application in	condition for allowan	ce because:				
12. ☐ Note the attached Information Disclosure Statement(s). (	PTO/SB/08) Paper No(s)						
13. Other:							

Continuation of 11, does NOT place the application in condition for allowance because:

The amendments now made to claim 42 by replacing the previous pleural limitation 'purified bacterial capsular polysaccharides' in lines 6 and 7 with the singular imitation 'the purified capsular polysaccharide' and by replacing the previous pleural limitation 'purified bacterial capsular polysaccharides' in line 9 with the stingular limitation the purified capsular polysaccharide' change the scope of the claim and raise new indefiniteness issue since these new limitations are inconsistent in scope with the other limitations 'purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 and 'the purified bacterial capsular polysaccharides' in lines 4 and 5 a

The amendment now made to claim 42 by deleting 'a' from the limitation 'at least' in line 9 of the claim renders the claim indefinite and/or incorrect.

/S. Devi/ Primary Examiner AU 1645

September, 2009